Gain Therapeutics (GANX) AI Stock Analysis

• Market Cap: $69.23M
• Dividend Yield: N/A
• Average Volume (3M): 989.48K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.84
• Revenue Growth: N/A
• EPS Growth: 42.29%
• Country: US
• Employees: 23
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.15
• Shares Outstanding: 38,462,086
• 10 Day Avg. Volume: 615,496
• 30 Day Avg. Volume: 989,479
• PEG Ratio: 0.05
• Price to Book (P/B): 6.73
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -2.62
• Enterprise Value/Market Cap: 0.88
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: -12.15
• Enterprise Value/Ebitda: -3.48
• 1Y Price Target: $7.50
• Price Target Upside: 321.35% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 4
• EPS Forecast (FY): -0.71
• Revenue Forecast (FY): N/A

• Rating: 46 Neutral
• Price Target: $2.00 ▲(12.36% Upside)

The score is mainly held back by weak financial performance (minimal revenue, significant losses, and ongoing cash burn). Technicals also lean negative in the near term (below 20D/50D with subdued momentum). A positive offset is the encouraging Phase 1b update and stated runway through year-end 2026, but valuation is constrained by negative earnings and no indicated dividend.

Positive Factors

Proprietary computational platform

A proprietary computational discovery platform is a durable competitive asset that can accelerate target identification and design across multiple programs. It can lower discovery costs, create repeatable pipeline opportunities, and support partnering/licensing strategies beyond any single asset.

Promising Phase 1b biomarker and safety data

Robust biomarker reductions with tolerability and a DMC recommendation to continue materially de-risk clinical development. Persistent target engagement and participant extension uptake strengthen the program's chance to reach meaningful clinical readthrough and attract partners or later-stage investors.

Low financial leverage

Very low debt reduces near-term financial risk and preserves flexibility common to early-stage biotech. With limited fixed obligations, management can prioritize R&D progress and strategic partnering without immediate debt servicing pressures, improving operational optionality over the next 2–6 months.

Negative Factors

Minimal revenue and recurring losses

The company remains development-stage with virtually no commercial revenue and sizable recurring losses. This structural lack of revenue undermines margin sustainability, increases reliance on external capital, and limits internal funding for program expansion absent partnerships or financings.

Persistent cash burn and negative free cash flow

Substantial, persistent negative operating and free cash flow across recent periods signals ongoing funding needs. Continued burn constrains the firm’s ability to broaden R&D or support multiple programs simultaneously and heightens the probability of dilutive financings before commercial inflection.

Ongoing dilution risk from equity offerings

Active at-the-market equity programs and prior sales indicate structural dependence on equity capital. Combined with a declining equity base noted in the balance sheet, this elevates dilution risk for shareholders and can restrict long-term return potential and planning autonomy for pipeline investments.

Gain Therapeutics Business Overview & Revenue Model

Company Description

Gain Therapeutics, Inc., a biotechnology company, engages in developing various therapies to treat diseases caused by protein misfolding. It focuses on rare genetic diseases and neurological disorders. The company uses its Site-Directed Enzyme Enhancement Therapy platform to discover allosteric sites on misfolded proteins and identify proprietary small molecules that bind these sites, restore protein folding, and treat disease. It is developing structurally targeted allosteric regulator candidates to treat various diseases, including Morquio B, GM1 gangliosidosis (GM1), neuronopathic Gaucher disease, GBA1 Parkinson's, Krabbe, and Mucopolysaccharidosis type 1 diseases. The company was founded in 2017 and is based in Bethesda, Maryland.

How the Company Makes Money

Gain Therapeutics primarily makes money through partnerships, collaborations, and licensing agreements with larger pharmaceutical and biotechnology companies. These partnerships usually involve upfront payments, milestone payments based on the achievement of development or regulatory milestones, and royalties on future sales of products developed using Gain's technology. Additionally, the company may receive research grants and funding for specific projects aimed at discovering therapies for rare diseases.

Gain Therapeutics Financial Statement Overview

Summary

Development-stage profile with effectively zero TTM revenue and sizable ongoing losses (TTM net loss ~$19.4M) plus persistent cash burn (TTM operating and free cash flow about -$17.3M). Balance sheet leverage is low (debt-to-equity ~0.06), but equity has compressed materially over time, increasing reliance on future funding.

Income Statement

TTM (Trailing-Twelve-Months) revenue is still effectively zero, and losses remain significant (TTM net loss of about $19.4M; EBIT/EBITDA also deeply negative). Historical revenue has been minimal and inconsistent (annual revenue near-zero in 2024; small revenue in 2020–2023), offering limited evidence of commercial traction. The main positive is that TTM losses are somewhat narrower than 2023–2024, but profitability is still far from breakeven and margins are structurally weak given the low revenue base.

Balance Sheet

Leverage is low (TTM debt-to-equity ~0.06), which reduces financial risk and gives flexibility typical of early-stage biotech. However, equity has declined meaningfully over time (from ~$34.8M in 2021 to ~$5.9M TTM), reflecting ongoing losses and potential future financing needs. Returns on equity are sharply negative (TTM ROE ~-2.89), highlighting that the capital base is being consumed rather than compounding.

Cash Flow

Cash burn is substantial and persistent: TTM operating cash flow is about -$17.3M and free cash flow about -$17.3M, with negative free cash flow across all years shown. TTM free cash flow deterioration versus the prior annual period is notable (free cash flow growth ~-6.23), suggesting burn has not stabilized. A modest positive is that cash outflow broadly tracks the net loss (free cash flow to net income ~1.0), but overall funding dependence remains high.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	0.00	0.00	55.18K	132.64K	133.93K	28.88K
Gross Profit	-4.99M	0.00	55.18K	-8.11M	-7.03M	28.88K
EBITDA	-17.40M	-20.27M	-22.17M	-17.76M	-13.82M	-3.47M
Net Income	-19.39M	-20.41M	-22.27M	-17.59M	-13.89M	-3.58M
Balance Sheet
Total Assets	10.97M	12.12M	18.61M	24.10M	38.99M	9.60M
Cash, Cash Equivalents and Short-Term Investments	8.81M	10.39M	16.79M	20.14M	36.88M	7.49M
Total Debt	180.94K	653.01K	1.03M	1.27M	1.61M	1.26M
Total Liabilities	5.06M	4.78M	6.03M	5.22M	4.17M	3.40M
Stockholders Equity	5.91M	7.34M	12.58M	18.88M	34.82M	6.20M
Cash Flow
Free Cash Flow	-17.30M	-18.90M	-18.88M	-14.81M	-12.46M	-3.26M
Operating Cash Flow	-17.30M	-18.87M	-18.87M	-14.69M	-12.37M	-3.24M
Investing Cash Flow	-43.45K	4.98M	10.22M	-14.77M	-94.21K	-20.83K
Financing Cash Flow	14.21M	13.01M	12.64M	-78.77K	41.77M	10.49M

Gain Therapeutics Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 1.78
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GANX, the sentiment is Negative. The current price of 1.78 is below the 20-day moving average (MA) of 2.20, below the 50-day MA of 2.88, and below the 200-day MA of 2.10, indicating a bearish trend. The MACD of -0.28 indicates Positive momentum. The RSI at 34.75 is Neutral, neither overbought nor oversold. The STOCH value of 33.39 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for GANX.

Gain Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
PRLD	47 Neutral	$104.74M	-1.26	-103.99%	―	250.00%	15.15%
GANX	46 Neutral	$69.23M	-2.78	-261.72%	―	―	42.29%
PMVP	46 Neutral	$57.47M	-0.67	-51.87%	―	―	-58.47%
ABVC	44 Neutral	$49.09M	-8.47	-40.32%	―	56.52%	75.22%
PSTV	40 Underperform	$40.69M	-0.13	―	―	-8.16%	22.44%

Gain Therapeutics Corporate Events

Gain Therapeutics Reports Encouraging Phase 1b Parkinson’s Data

On December 18, 2025, Gain Therapeutics reported exploratory endpoint data from Part 1 of its Phase 1b clinical study of GT-02287 in people with Parkinson’s disease, showing that all participants with elevated cerebrospinal fluid glucosylsphingosine experienced large reductions toward levels seen in healthy individuals after 90 days of treatment. The 21-patient study saw 19 complete the three‑month dosing period and 15 opt into a nine‑month extension that is expected to conclude in September 2026, with GT‑02287 remaining generally well tolerated at projected therapeutic exposures and the data monitoring committee recommending continuation without changes; combined with Phase 1 data in healthy volunteers demonstrating favorable safety, central nervous system exposure and target engagement, and confirmation that its current capital should fund operations through the Phase 1b extension and year‑end 2026, the company has strengthened its clinical and financial footing in the competitive Parkinson’s drug development space.

The most recent analyst rating on (GANX) stock is a Buy with a $8.00 price target. To see the full list of analyst forecasts on Gain Therapeutics stock, see the GANX Stock Forecast page.

Gain Therapeutics Announces New Stock Offering Program

Gain Therapeutics, Inc., a company involved in the sale of common stock, announced on November 28, 2025, that it has filed a prospectus supplement with the SEC for an ‘at the market offering’ program. This program allows the company to offer and sell up to $35,530,980.56 of its common stock through Oppenheimer & Co. Inc. as the sales agent. As of the announcement, the company has already sold $14,469,019.44 worth of stock under the existing Equity Distribution Agreement. The legal opinion regarding the validity of this stock offering has been provided by Lowenstein Sandler LLP.

The most recent analyst rating on (GANX) stock is a Buy with a $5.00 price target. To see the full list of analyst forecasts on Gain Therapeutics stock, see the GANX Stock Forecast page.